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Mutation analysisSARS-CoV-2 has caused COVID-19 outbreak with nearly 2 M infected people and over 100K death worldwide,
until middle of April 2020. There is no confirmed drug for the treatment of COVID-19 yet. As the disease spread
fast and threaten human life, repositioning of FDA approved drugsmay provide fast options for treatment. In this
aspect, structure-based drug design could be applied as a powerful approach in distinguishing the viral drug tar-
get regions from the host. Evaluation of variations in SARS-CoV-2 genomemay ease finding specific drug targets
in the viral genome. In this study, 3458 SARS-CoV-2 genome sequences isolated from all around the world were
analyzed. Incidence of C17747T and A17858Gmutations were observed to be much higher than others and they
were on Nsp13, a vital enzyme of SARS-CoV-2. Effect of these mutations was evaluated on protein-drug interac-
tions using in silicomethods. Themost potent drugswere found to interact with the key and neighbor residues of
the active site responsible fromATP hydrolysis. As result, cangrelor, fludarabine, folic acid and polydatinwere de-
termined to be themost potent drugs which have potency to inhibit both the wild type andmutant SARS-CoV-2
helicase. Clinical data supporting these findings would be important towards overcoming COVID-19.
© 2020 Elsevier B.V. All rights reserved.1. Introduction
Coronaviruses aremembers of the Coronaviridae family, and they are
taxonomically classified into four major genera: Alphacoronavirus,
Betacoronavirus, Gammacoronavirus and Deltacoronavirus by phyloge-
netic studies [1]. SARS-related coronaviruses belong to the
Betacoronavirus genus are important respiratory pathogens that have
caused worldwide outbreaks such as Severe Acute Respiratory Syn-
drome (SARS), Middle East Respiratory Syndrome (MERS) over the
last 20 years and now COVID-19 [1,2]. COVID-19 disease caused by se-
vere acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also
known as 2019 novel coronavirus (2019-nCoV) was reported from
Wuhan, China for the first time in December 2019 and the disease
caused by SARS-CoV-2 was declared as pandemic by WHO in March
11th 2020 [3,4]. According to the Centers for Disease Control and Pre-
vention (CDC), there is not any available drug for SARS-CoV-2 [5].
There are nearly 2,000,000 cases and 120,000 deaths up to April 14th,
2020 [3] and these numbers are increasing day by day..edu.tr (D. Turgut-Balik).As the number of cases and deaths are increasingworldwide, the ge-
nomic characterization of SARS-CoV-2 has become of key importance
for treatment as well as the vaccine development and diagnosis of the
disease [6,7]. The first genome sequence of the SARS-CoV-2 has been
entered into the database byWu et al. in February 2020 [8]. Coronavirus
genome size approximately 30,000 bases and present as single-
stranded positive RNA (+ssRNA) with 5′-cap and 3′-poly-A tail [9].
They have 6 open reading frames (ORFs) and the first ORF (ORF1a/b),
which comprise approximately 67% of the entire genome, encodes 16
non-structural proteins (Nsps) [1]. The remaining ORFs encode 4
major structural proteins, which are spike surface glycoprotein (S),
small envelope protein (E), matrix protein (M), nucleocapsid protein
(N), and accessory proteins [1,9]. Differences between genomes could
be evaluated for both diagnosis and treatment approaches. Total of
380 substitutions between SARS coronavirus (SARS-CoV) and SARS-
CoV-2 at the amino acid level have been reported on a SARS-CoV-2 ge-
nome study [1]. Furthermolecular and structural studies should be con-
ducted to evaluate effects of these substitutions on the functionality and
pathogenesis of SARS-CoV-2 [1]. Along with the vital proteins of SARS-
CoV, helicase has been studied widely [10]. Helicases are NTP-
dependent proteins and involved in cellular mechanisms like viral
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codes viral helicase for replication and it is considered as a future candi-
date for antiviral targets [9,13,14].
SARS-CoV helicase named as Nsp13 in superfamily 1 helicase family
with the activity of 5′-3′ RNA/DNA helicase RTPase and the enzyme is
known to be a part of the replication and translation complex which is
required for life cycle of SARS-CoV [10,13,15–17]. SARS-CoV Nsp13 has
five domains which are zinc-binding domain, stalk domain, 1B domain,
1A domain and 2A domain [18,19]. The 1B, 1A and 2A domains have
been studied for SARS-CoV and demonstrated that they are involved
in the dsDNA unwinding process [18,20]. Also, the substrate, transition
and product states of SARS-CoVNsp13 observations showed the coordi-
nation between the 1A and 2A domains during translocation [18].
Helicase motifs similarly conserved in a variety of viruses like SARS-
CoV [13], but also sequence difference has been seen in their coding se-
quence [13].Mutations onNsp13 have been studied on a type of corona-
virus called avian infectious bronchitis virus (IBV), specifically the lethal
effect of Arg132/Pro mutation on IBV Nsp13 has been demonstrated
[21]. Furthermore, S259/L mutation on the SARS-CoV Nsp13 has been
reported to change the drug efficacy [22]. Moreover, a study shows
the interaction between some small molecules and NTPase active site
residues which are conserved in SARS-CoV-2 Nsp13 and this justifies
targeting SARS-CoV-2 helicase to study for enzyme inhibition studies
[19].
In this study, we have analyzed genome sequences of SARS-CoV-2
isolates to evaluate the effects of substitutions available on Nsp13. We
have evaluated the impact of substitutions causing missense mutations
on protein structure by homology modeling and molecular dynamic
simulations. Furthermore, high-throughput virtual screening and mo-
lecular docking were applied to prioritize candidate inhibitors for the
wild type and mutant SARS-CoV-2 helicases from the pool of FDA-
approved drugs.
2. Materials and methods
2.1. Nucleotide and amino acid sequence data, alignment and mutation
determination
The first genome of the SARS-CoV-2 was sequenced and entered the
GenBank database with an accession number of MN908947.1, after the
first case of COVID-19 confirmed and an etiological agent of the disease
identified by Wu et al. in December 2020 [8]. This sequence was then
curated by NCBI staff, reviewed by RefSeq [23] and NC_045512.2 was
appointed as reference genome for SARS-CoV-2. Complete genome se-
quences of nearly 5000 SARS-CoV-2 isolates have been submitted to
GISAID EpiCoV database [24,25] from all around the world, mostly
from China and United States of America up to April 7th, 2020. In this
study, reference genome sequence of SARS-CoV-2 was downloaded
from GenBank [26] and all other SARS-CoV-2 isolate genome sequences
with high coveragewere downloaded from GISAID EpiCoV for the anal-
ysis of substitutions. The accession numbers and annotations such as
taxonomic name of viruses, isolate names, isolation dates and places,
are given in Supplementary Table 1.
In this study, the complete genome sequences from 3458 isolates
were aligned using a software (software not published yet) written in
Python language based on sequence alignment algorithms with differ-
ent strategies and validated with multiple alignment program MAFFT
v7 [27,28] to evaluate sequence differences among SARS-CoV-2 ge-
nomes isolated in different countries. The genotype differences among
SARS-CoV-2 isolate genomeswere determined visually, using the align-
ment viewer JalView v2.10.5 [29].
Mutations causing amino acid exchanges in vital genes for the life
cycle of the virus and present on more than 10% of the isolate genome
sequences are listed. Reverse engineering showed that two of the
most seen mutations are in the coding region of helicase and near the
active site of the enzyme. Therefore, helicase was selected as the target1688protein in this study. Amino acid sequences of SARS-CoV-2 Nsp13 were
obtained from the GenBank database. Nsp13 protein sequences of wild
type isolate (Wuhan-Hu-1: YP_009725308.1) and two mutant isolates
(USA/MN3-MDH3/2020: QIK02943.1 region: 5325-5925 and USA/
WA6-UW3/human/2020: QII87804.1 region: 5325-5925) were aligned
using The EuropeanBioinformatics Institute (EMBL-EBI)MUSCLEmulti-
ple sequence alignment tool [30,31], to perform multiple protein se-
quence analysis.
2.2. Comparative modeling of wild type and mutant SARS-CoV-2 helicase
Reference amino acid sequence for SARS-CoV-2Nsp13was retrieved
from NCBI database (Accession no: YP_009725308.1). The reference se-
quence was identified as wild type SARS-CoV-2 helicase in this study
and used for searching template structure from BLAST program
(https://blast.ncbi.nlm.nih.gov). Firstly, the wild type helicase was
modeled using both MODELLER 9.15 [32] and SWISS-MODEL [33] pro-
grams. In MODELLER 9.15, the amino acid sequence of the wild type
helicase and the three dimensional structure file of the template protein
were entered as input data. 100 models were generated and the best
model was identified according to the Discrete Optimized Protein En-
ergy (DOPE) score. In SWISS-MODEL server, the wild type helicase
amino acid sequence was entered and the model was built based on
the selected template structure. Quality of the models were checked
by using ERRAT, RAMPAGE, ProSA, ProQ and VERIFY3D servers
[34–38] and superimposition of themodels with the template structure
were performed by utilizing UCSF Chimera ver1.10.1 software [39].
After evaluation of the initial quality scores of resultant models, struc-
ture of the mutant SARS-CoV-2 helicase was modeled using SWISS-
MODEL [33]. Then, the validation steps were repeated for the mutant
helicase model.
2.3. Molecular dynamics simulations of homology models of SARS-CoV-2
helicases
The structure-function relationship of a molecule directly depends
on themovement dynamics of themolecule. Molecular dynamics simu-
lationsmethods define themovements of proteins and help understand
the functions of their structural-dynamic properties. In this study, struc-
tural changes of mutant and wild type SARS-CoV-2 helicase, whose 3D
structure was defined by homology modeling method, were investi-
gated. Atomic fluctuation and vibration within femtosecond; displace-
ment of secondary structures and side chain transformations within
picosecond; movement of secondary structures, protein folding within
nanosecond; membrane movements, conformational change, mole-
cules association-disassociation takes place within the microsecond
time interval [40]. Both mutant and wild type SARS-CoV-2 helicases
were simulated using molecular dynamic methods for 50 ns to reveal
the effect of amino acids changes on the function of the protein. If the
similarity between the template andmodel ismore than 50%, homology
models can be used as a reliable model in drug discovery studies [41].
Since the similarity between the template and structure was 98.5% in
this study, the homology model built was more reliable. This reason,
the simulation will be sufficient for 50 ns for the displacement of the
secondary structures in the 3D structure of both helicases and to reach
equilibrium. 10 Å size octahedral periodic box is defined using
AMBER14 tLeap [42], FF14SB charge model [43] and TIP3PBOX [44] to
create topology and coordinate files wild type and of mutant 3D struc-
tures in this method. The system was neutralized by adding Na+ and
Cl-. Homology models were minimized to remove bad interactions
and clashes using 9 Å cutoff at constant volume. The first 10,000 steps
quickly reach the local minimum point with the steepest descent algo-
rithm [45], and then homology model were minimized at 90,000 steps
with the conjugate gradient algorithm [46] to reach the global mini-
mum. The systems were heated to 300 K with Langevin Thermostat
[47] with a collision frequency of γ = 10.0 ps−1 during 200 ps with 2
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the system. As a last step, the simulation of the systems were run at a
constant temperature and pressure using a weak coupled temperature
algorithm Berendsen [48] during 50 ns with 2 femtosecond steps and
SHAKE algorithm [49] was applied to restraint all atoms during dynam-
ics run. The deviation between the positions of the Cα backbone carbon
atoms were evaluated with respect to the root mean square deviation
(RMSD) and β-factor read from MD simulation trajectory file using
CPPTRAJ [50] during 50 ns for complexes and the plots were drawn
using Gnuplot [51].
2.4. High-throughput virtual screening and molecular docking
FDA approved drug structures were obtained from the ZINC15 data-
base as SDF format [52]. Drug structures were prepared and the
ionisation states were generated using LigPrep (LigPrep, Schrödinger,
LLC, New York, NY, 2020). Helicase structures were prepared using the
Protein Preparation Wizard (Protein Preparation Wizard, Schrödinger,
LLC, New York, NY, 2020) from Maestro (Maestro, Schrödinger, LLC,
New York, NY, 2019-1) by adding H atoms and defining protonation
states. ATP-binding pocket as docking sitewas set up using the Receptor
Grid Generation Panel. High-throughput virtual screening was carried
out using Glide (Glide, Schrödinger, LLC, New York, NY, 2020) by
selecting the top 10% most ideal drugs in the first stage, which then
evaluated by Standard Precision (SP) docking. Ten percent of the
drugs from the SP stage were then subjected to an Extra Precision
(XP) docking process. After docking stage, post-processing with Prime
was conducted for MM-GBSA binding energy calculation (Prime,
Schrödinger, LLC, New York, NY, 2020).
3. Results and discussion
3.1. Nucleotide and amino acid sequence data, alignment and mutation
determination
By 7th April 2020, 3458 genome sequences were determined by se-
quencing the SARS-CoV-2 genome from58 countries in different studies
and all deposited in databases (Supplementary Table 1).
In this study, all these sequences were downloaded and aligned
based on the reference sequence (NC_045512.2; 1-29870) that consist
of 11 gene regions; ORF1ab (266-21555), S (21563-25384), ORF3a
(25393-26220), E (26245-26472), M (26523-27191), ORF6 (27202-
27387), ORF7a (27394-27759), ORF7b (27756-27887), ORF8 (27894-
28259), N (8274-29533), ORF10 (29558-29674).Fig. 1. Alignment of helicase amino acid sequences from four isolates of SARS-C
1689Although there are manymutations spread on the whole genome of
SARS–CoV-2, in our study, we focused on the substitutions causingmis-
sense mutations on the vital enzymes of virus and consistent, consider-
ing the countries anddates of the isolates. Accordingly,we have selected
twomutations C17747T and A17858G on the gene sequences encoding
helicase beingpresent simultaneously in 11,6%of 3458 isolates (Supple-
ment Fig. 1). The SARS-CoV-2 isolate, bearing two substituents on
helicase, was observed to be spread all over 3 continents, North
America especially. The genome sequence of the isolate harboring
these two mutations simultaneously was first uploaded to the GISAID
from Washington, USA on February 20th, 2020(EPI_ISL_413456);
33 days after the first isolate genome submitted to the database from
the USA (EPI_ISL_404895). This may be an indicator to understand
tracking the spread and evolution of the disease. The rate of isolate bear-
ing thesemutations is 52% (408mutants over 777 isolates) in the USA &
Canada, 9% (33 mutants over 355 isolates) in Oceania and 3% (10 mu-
tants over 292 isolates) in Iceland and totally 11,6% of 3458 isolates. Ac-
cording to the genome sequence data by 7 April 2020; there is no isolate
harboring C17747T and A17858G mutations simultaneously in Asia,
Africa and continental Europe yet (Supplement Fig. 1).
Two substitutions causing missense mutations (P504L and Y541C)
in the region encoding Nsp13 in the SARS-CoV-2 genome is shown in
Fig. 1. Substitutions on Nsp 13 lower than 10% were ignored. Studies
with SARS-CoV show that helicase is a vital protein for replication and
pathogenesis [10] and potential target for antiviral candidates
[9,13,14]. Therefore, effects of these exchanges on the helicase was fur-
ther evaluated by structural studies to determinewhether these specific
mutations gained by SARS-CoV-2 isolates are vital for the helicase activ-
ity to possibly consider targeting this enzyme towards repositioning
some currently available drugs to fight with COVID-19 infections.3.2. Comparative modeling of wild type and mutant SARS-CoV-2 helicase
structures
Amino acid sequence of wild type SARS-CoV-2 helicase was used to
search a template structure by using PSI-BLAST algorithm from BLASTP
program in NCBI. Human SARS coronavirus Nsp13 (PDB ID: 6JYT) was
selected as template structure based on 98.5% sequence percentage
identity. In addition, the same structure was also chosen as template
structure for SARS-CoV-2 Helicase model in other studies [53,54]. At
the beginning, only the wild type helicase structure was built using
MODELLER 9.15 [32] and SWISS-MODEL [33] programs. The best
model that was generated by MODELLER 9.15, was selected based on
the minimum DOPE score which was −64,065.48828. Quality of theoV-2; Wild Type: Wuhan-Hu-1 and mutant: USA/WA6-UW3/human/2020.
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VERIFY3D servers [34–38]. Overall quality factor was identified as
56.661 by ERRAT server. This score was very low and very faulty resi-
dues were observed. Based on the Ramachandran plot of the model,
90.2%, 8.2% and 1.7% residues were found in favoured region, allowed
region and outlier region, respectively. Z-score of the model was
−8.75 and the model was found in the native proteins range that
were identified by X-ray crystallography. LGscore was calculated as
4.906 by PROQ server and 85.36% of the residues of the model have av-
eraged 3D-1D score by VERIFY3D server. According to PROQ and
VERIFY3D results, it could be identified as a good model [36,38]. Super-
imposition of the model and the template structure shows that the
RMSD (root-mean-square-deviation) value was 0.283 Å. Overall of
these validation results were compared with the quality scores of the
model that was built by SWISS-MODEL (Table 1). At the end, SWISS-
MODEL server was evaluated as more suitable than MODELLER 9.15
for modeling wild type and mutant helicases.
Amino acid sequences of wild type and mutant SARS-CoV-2
helicases were entered into SWISS-MODEL web server [30] for
searching a template structure. The template structure (PDB ID: 6JYT)
had 99,83% and 99,50% the percentage sequence identity with wild
type and mutant helicase sequences, respectively. Structural models
were then validated as shown in Table 1. ERRAT overall quality factors
were identified as 81.2613 and 81.522 forwild type andmutantmodels,
respectively. According to RAMPAGE server results of both models,
86.5%, 11.3% and 2.2% residues were found in favoured, allowed and
outlier region, respectively. The percentage of the residues in favoured
region was found to be lower than the expected. On the other hand,
the Ramachandran plot results of the template structure had been ob-
tained as 80%, 15% and 5% residues in favoured region, allowed region
and outlier region, respectively in X-ray structure validation report
(PDB ID: 6JYT) (www.rcsb.org) and Ramachandran plot results of the
models were identified as similar with the template structure scores.
Therefore, the models could be evaluated as acceptable for the further
analyses. Z-scores of wild type and mutant helicase models were calcu-
lated as−8.72 and−8.55, respectively. According to these scores, both
models were found in the score range of the native proteins determined
by X-ray crystallography methods. LGscores were identified as 5.196
and 5.140 for wild type and mutant models, respectively. These scores
were observed above 4 and the models were determined as extremely
good model according to PROQ server [38]. Based on VERIFY3D server
results, 88.09% and 87.92% residues of wild type and mutant helicase
models had averaged 3D-1D scores. These scores were found above
80% and the generated models were evaluated as good models by
VERIFY3D server [36]. RMSD values were identified as 0.128 Å and
0.126 Å for wild type and mutant models, respectively. The values
showed that wild type and mutant helicase models were highly similarTable 1
The quality validation of wild type and mutant SARS-CoV-2 helicase models.
Server SARS-CoV-2 Helicase WT by MODELLER 9.15 SARS-Co
ERRAT 56.661 81.2613
RAMPAGE Number of residues in favoured region: 514
(90.2%)
Number of residues in allowed region: 67
(8.2%)








PROSA z-score −8.75 (the model in X-ray region) −8.72 (
PROQa Predicted LGscore: 4.906 Predicte







0.283 Å 0.128 Å
a Quality ranges of PROQ scores: LGscore>1.5 fairly goodmodel; LGscore>2.5 very goodmo
good model; MaxSub>0.8 extremely good model.
b The amino acids must be scored as at least 80% for evaluation as a good model.
1690to template protein. Based on the quality scores and the overall struc-
tural features, the models were found to have sufficient quality and ac-
ceptable for the further structural studies.
3.3. Molecular dynamics simulations of homology models of SARS-CoV-2
helicases
Homology models of mutant and wild-type SARS-CoV-2 helicases
were simulated for 50 ns to minimize bad interactions in the structure
and to stabilize thermodynamically secondary structures. In this way,
the difference in sites P504L and Y541C, where there are amino acid
changes, can be analyzed with reference to the wild type. The RMSD
graph showing deviations based on the Cα backbone carbon atoms in
SARS-CoV-2 helicases for 50 ns was plotted using Gnuplot. According
to the graph, both mutant and wild-type SARS-CoV-2 helicases were
equilibrated after almost 7–8 ns, and especially helicases showed con-
sistent and constant deviation after 9 ns (Fig. 2a). Root-mean-square de-
viations (RMSD) of the Cα backbone carbon atoms for mutant and wild
type SARS-CoV-2 helicases were calculated as 3.51 Å and 3.50 Å, respec-
tively. According to the β-factor graph, it was observed that there was a
fluctuation in similar regions, but thefluctuation of themutantwas gen-
erally higher than the wild type (Fig. 2b).
The first 100 residues of helicase are known as zinc binding domains,
and fluctuations were much because of outside the tertiary structure.
The region with residues between 315 and 365, defined as 2A domain,
was one of the regions where fluctuation was high since it did not
have a secondary structure. The noticeable difference in wild-type
helicase is that the site between 410 and 420 shows higher fluctuation.
The reason for this fluctuationwas investigated and it was revealed that
the secondary structure α-helix was formed when the 3D-dimensional
structure was compared with the mutant, but this site was far from the
ATP-binding site (Fig. 3). The most important difference in the mutant
SARS-CoV-2 helicase was observed between 490 and 500 residues.
The 3D-dimensional structure of the helicase has been analyzed and it
reveals that the α-helix structure is formed in the mutant helicase in
this site, which is not a secondary structure of the wild type helicase.
Due to the α-helix structure formed in the mutant helicase, the α-
helix structure between 510 and 520 has been displaced out of the
ATP-binding site (Fig. 3).
Residue 504 was substituted from proline (wild type) to leucine
(mutant) in the mentioned mutation P504L and both residues are
non-polar and aliphatic residues. But the proline has a different cyclic
structure and the amino group in its structure is directly linked to the
main chain. In addition, when the peptide bond to the proline in a pep-
tide chain, the amino group can only act as a hydrogen acceptor because
of attached to the main ring. It takes a role as a restrictive in the forma-
tion of secondary structures of proteins and often disrupts theseV-2 Helicase WT SARS-CoV-2 Helicase Mutant
81.522
of residues in favoured region: 514
of residues in allowed region: 67
of residues in outlier region: 13
Number of residues in favoured region: 514
(86.5%)
Number of residues in allowed region: 67
(11.3%)
Number of residues in outlier region: 13
(2.2%)
the model in X-ray region) −8.55 (the model in X-ray region)
d LGscore: 5.196 Predicted LGscore: 5.140
f the residues have averaged 3D-1D
.2
87.92% of the residues have averaged 3D-1D
score ≥0.2
0.126 Å
del; LGscore>4 extremely goodmodel. MaxSub>0.1 fairly good model; MaxSub>0.5 very
Fig. 2. a) Root-mean-square deviations (RMSDs) and b) fluctuations (bfactor) of the Cα backbone carbon atoms for mutant (green) and wild type (red) SARS-CoV-2 helicases of MD
simulation during 50 ns.
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one of the residueswith a branched side group and ismostly involved in
alpha helix structures in the protein folds [56]. Therefore, this change
will differentiate the 3-dimensional structure of the protein, and the
change of secondary structures among the 490–520 residues seen in
the β-factor plot was based on this reason.
The other mutation was tyrosine (541), which has a non-polar, par-
tially hydrophobic and aromatic ring-containing side group inwild type
helicase, has turned into a cysteine (541) containing SH group in theFig. 3. Superimpositions of mutant (green) and wild type (white) SARS-CoV-2 helicases after
residues are shown in yellow, two mutations (P504L and Y541C) are shown in red.
1691polar, uncharged side group. Tyrosine is usually located in hydrophobic
cavities of proteins and interacts with non-protein ligands. They usually
form hydrophobic hot spots in proteins thanks to the aromatic side
groups [57]. However, cysteine mostly contributes to enzymatic reac-
tions with its thiol side group and this group is very active. Sulfhydryl
group is a strong reducing agent and provides redox reactions in most
environments. In addition, another important feature of cysteine is its
ability to form sulfur bridges with covalent bonds between two cyste-
ines. It plays a vital role in the formation of secondary, tertiary andMD simulation. The representation in the hexagon is the ATP-binding site and the active
Fig. 4. Calculation of distances between domains after MD simulation. a) SARS-CoV-2 wild type helicase b) SARS-CoV-2 mutant (P504L and Y541C) helicase.
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maintains the rigidity of these structures. Often these dimer formations
are seen in extracellular proteins. These dimer formations from intracel-
lular proteins are rarely seen and can even be rarely seen in the extracel-
lular domains of cell membranes [58].
As a result of these two mutations, the gap between 2A and 1B do-
mains widened and it was calculated as 10.7 Å in wild type and 15.0 Å
in mutant type, respectively (Fig. 4a). Likewise, the gap between the
2A and the 1A domain widened and was 5.1 Å in the wild type and
11.4 Å in the mutant type, respectively. While the wild type helicase
2A, 1A and 1B domainswere closer andmore compact, the distances be-
tween these domains have expanded in the mutant type helicase
(Fig. 4b).
3.4. High-throughput virtual screening and molecular docking
FDA approved drugs were screened and docked to the ATP-binding
site which was found between 2A and 1A domains of the SARS-CoV-2
wild type and mutant helicases. Both P504L and Y541C mutations
were in the 2A domain and caused a more hydrophobic 2A domain. Es-
pecially, Y541C mutation was very close to the ATP hydrolysis site and
previous in silico study on SARS-CoV-2 helicase showed that the com-
pounds interacted with nearby residues including D534, S535 and
S539 [19]. As shown by molecular dynamics simulations, movements
of the P-loop (Fig. 4) and Gln537-Asp542 loop (Fig. 4) caused to
narrower ATP-binding site where drugs mainly interacted with
Gln537, Gly538 and Glu540 residues in wild type helicase. In our
high-throughput screening and molecular docking study the most po-
tent drugs were found to interact with the key and neighbor residues
of the active site responsible fromATPhydrolysis. Four drugs (cangrelor,
fludarabine, folic acid and polydatin) interactedwith bothwild type andTable 2
Molecular docking results of FDA drugs with the wild type SARS-CoV-2 helicase.
Drug name Glide energy Glide emodel XP GScore XP
Cangrelor −64.566 −88.135 −11.478 −
Pemetrexed −56.766 −75.064 −10.192 −
Fludarabine −48.921 −57.730 −9.769 −
Folic acid −58.839 −87.011 −9.424 −
Cidofovir −42.543 −52.251 −9.204 −
Zanamivir −34.220 −49.983 −9.186 −
Polydatin −53.163 −69.046 −7.276 −
Sapropterin −33.493 −43.767 −6.904 −
Ertapenem −51.556 −68.522 −6.782 −
Ribavirin −42.006 −47.391 −6.549 −
Drugs interacted with both enzymes are shown in bold. Values are in kcal/mol.
1692mutant helicases. However, XP GScores were found to be lower (indi-
cates stronger binding) in wild type except for polydatin (Tables 2, 3).
In detail, cangrelor (an antiplatelet drug) had the lowest XP GScore
(−11.478 kcal/mol and −11.348 kcal/mol) and interacted with the
wild type and mutant helicases. Cangrelor was involved in interaction
with Thr286, Gly287, Lys320, Asp374, Arg442, Arg443, Glu540 and
Thr286, Gly287, Ser289, Lys320, Arg443 in wild type and mutant
helicases, respectively (Figs. 5 and 6). Fludarabine also interacted with
both enzymes and showed lower score in the wild type helicase (XP
GScore −9.769 kcal/mol) (Table 2). Fludarabine was involved in the
H-bond interaction with the Thr286, Arg567 and Glu540 in both en-
zymes (H-bond and salt-bridges with Arg443 in mutant and wild type
enzyme, respectively) while Gly287, Ser289 and Ala316 interaction
was seen only inmutant structure. The other chemical structure docked
to both sites was folic acid which XP GScore was lower in wild type
when comparedwith themutant helicase (Tables 2, 3). Folic acid is a co-
factor required for synthesis of purines and pyrimidines [59]. It was
found that to interact with the key residues including Lys288 and
Gln404 in wild type, and Lys288 and Asp374 inmutant enzymes. More-
over, polydatin was also docked to the both sites and formed H-bonds
with the key residues including Lys288 and Arg567 in wild type and
mutant structures, respectively (Figs. 5 and 6).
Cangrelor is an antiplatelet drug [60] and a drug repositioning study
for the antiviral therapy has not been shown yet, to our knowledge.
Fludarabine is an effective drug for treatment of chronic lymphocytic
leukemia [61,62]. Besides this drug has not shown anti-viral activity
clearly, a drug combination with azidothymidine was evaluated against
HIV infection in 2000. The study showed that fludarabine could be a part
of themurine AIDS treatment [63]. Polydatin has antitumor, antioxidant
and anti-inflammatory effects [64]. Furthermore, it is also studied as an
antiviral agent for enterovirus 71 (EV71) infection but showed weakHBond XP Lipophilic EvdW XP Electro MMGBSA dG Bind
3.016 −2.762 −1.454 −47.46
2.887 −1.992 −1.117 −38.65
3.850 −1.288 −1.736 −19.86
3.012 −2.014 −1.439 −32.18
3.884 −1.187 −1.637 −18.76
6.762 −0.791 −1.617 −25.45
2.843 −3.182 −1.326 −44.52
4.104 −1.357 −1.199 −23.80
2.810 −2.294 −1.185 −9.16
2.873 −1.121 −2.274 −23.49
Table 3
Molecular docking results of FDA drugs with the mutant SARS-CoV-2 helicase.
Drug name Glide energy Glide emodel XP GScore XP HBond XP Lipophilic EvdW XP Electro MMGBSA dG Bind
Cangrelor −61.855 −80.025 −11.348 −3.892 −2.454 −1.993 −42.61
Leucovorin −51.466 −68.458 −8.285 −3.830 −1.819 −1.376 −29.14
Polydatin −42.337 −60.146 −8.072 −4.454 −2.079 −1.723 −53.16
Fludarabine −44.222 −55.772 −7.176 −2.962 −1.199 −1.465 −23.13
Folic acid −50.778 −71.383 −7.001 −2.983 −1.804 −1.162 −34.18
Methotrexate −51.585 −67.232 −6.626 −2.279 −1.856 −1.159 −36.97
Milrinone −30.945 −40.789 −6.253 −0.944 −3.173 −0.296 −36.10
Drugs interacted with both enzymes are shown in bold. Values are in kcal/mol.
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resveratrol which is suggested as an effective antiviral agent for MERS-
CoV virus infection by decreasing an essential nucleocapsid protein for
virus replication [66]. Also, resveratrol is an ATPase inhibitor and
showed an inhibitory action on Zika virus helicase and protease [67].
The top drugs interacting with the ATP-binding pocket of the wild
type SARS-CoV-2 helicase (cangrelor, pemetrexed, fludarabine) and ad-
ditional the two other drugs (cidofovir and ribavirin) are used in viral
therapy, are pyrimidine/purine-based drugs [68]. Pemetrexed is an
antifolate chemotherapy drug that is effective for multiple cancer
types [69,70] and its antiviral effects have not been investigated yet.
Other drugs interacting with wild type SARS-CoV-2 helicase were
found to be pemetrexed, cidofovir, ertapenem and sapropterin.
Pemetrexed was the second compound according to the XP GScore
(−10.192 kcal/mol) and involved in the interaction with the residues
in the pocket including Pro284, Thr286, Lys320, Gln404, Arg443 and
Gly538 (Supplement File 1, Fig. 1) in wild type helicase. Cidofovir is
used in the treatment of cytomegalovirus (CMV) retinitis infections in
patients with AIDS and inhibits DNA polymerisation by competing
deoxycytidine triphosphate [71]. Cidofovir was bound to the ATP-
binding site by interacting Pro284, Thr286, Asp374, Arg443 and
Arg567 residues (Supplement File 1, Fig. 2) and XP GScore was found
to be −9.204 kcal/mol.Fig. 5.Molecular docking views of drugs in the ATP-binding site of wild type SARS-CoV-2 heli
(c) cangrelor, (d) polydatin, (e) folic acid.
1693Ertapenem is a broad-spectrum antibiotic drug which exerts action
by inhibiting cell wall synthesis [73]. In the wild type docking site, it
was found to interact with Thr286, Lys288, Arg443 and Glu540 residues
(Supplement File 1, Fig. 5). Zanamivir interacted with the Lys288,
Ala316, Gln404, Arg443, Gln537 and Glu540 (Supplement File 1,
Fig. 3) of wild type helicase and XP GScore (−9.186 kcal/mol) was
found to be very close to the cidofovir.
Sapropterin, is a natural cofactor for phenylalanine hydroxylase,
which is used to treat the patients with tetrahydrobiopterin deficiency
[74] and to our knowledge its antiviral effect has not been reported
yet. It was found that the sapropterin interacted within the ATP-
binding site with Gln404 and the residues adjacent to the mutation
site of Y541C (Gln537, Gly538, Glu540) (Supplement File 1, Fig. 4). Riba-
virin shows antiviral activity against a wide range of DNA and RNA vi-
ruses and is used especially in the treatment of chronic Hepatitis C
virus (HCV) infections [75,76]. Ribavirin and drug combinations includ-
ing ribavirin were applied to the patients with SARS and MERS [77].
Recently, ribavirin is suggested for treatment of SARS-CoV-2 infections
[78] and in several drug repurposing studies, this drug was mentioned
as a potential therapeutic agent against the COVID-19 disease
[53,79,80]. In addition, ribavirin derivatives were shown as potent
HCV helicase inhibitors [81,82] and some docking studies predicted
that this drug could be a potential inhibitor for virus helicases [83,84].case. (a) Surface (right) and cartoon (left) views of all poses in the cleft. (b) Fludarabine,
Fig. 6.Molecular docking views of drugs in the ATP-binding site of mutant SARS-CoV2 helicase. (a) Surface (right) and cartoon (left) views of the all poses in the cleft. (b) Fludarabine,
(c) cangrelor, (d) polydatin, (e) folic acid.
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Glu540 residues of wild type helicase (Supplement File 1, Fig. 6). In-
terestingly, ribavirin and zanamivir have been shown to interact
only with the wild type enzyme and not with the mutant type in
this study. Although ribavirin is recommended for the treatment of
SARS-CoV-2 infections [78], and also suggested as potential thera-
peutic agent in some drug repositioning studies [79,80], a study re-
ported that some antiviral drugs including ribavirin and zanamivir
were ineffective and not recommended to treat COVID-19 [85]. This
could be in a well support of our study that some specific mutations
may alter interaction of some drug molecules with the proteins and
so loss of this interaction may end up failed treatments. This empha-
sizes the importance of evaluating clinical outcomes in combination
to genome variation studies.
On the other hand, leucovorin, milrinone and methotrexate were
bound to the ATP-binding site in mutant SARS-CoV-2 helicase only.
Methotrexate (a folate antagonist) is known to be a drug with anti-
cancer and anti-rheumatoid effects by acting on dihydrofolate re-
ductase enzyme in humans [86]. Its antiviral effect was reported
based on studies of Zika Virus which was found to show response
against the methotrexate treatment by reducing its replication [86].
Leucovorin is a derivative of tetrahydrofolic acid and used to coun-
teract the toxic effects of methotrexate in chemotherapy and reposi-
tioning to enhance the antitumor activity of other small molecules
[87]. Docking score of leucovorin (−8.285 kcal/mol) was lower
than the folate antagonist methotrexate (XP GScore −6.626 kcal/
mol) and the folic acid (XP GScore −7.001 kcal/mol) (Table 3).
Leucovorin, milrinone and methotrexate interacted with the resi-
dues in the docking site including Thr286, Gly287, Lys288 (pi-cation
interaction with Methotrexate), Ser289, Ser310, Asp374, Glu375,
Ser377, Arg443, Gln404, Leu405 and Arg567 (Supplement File 2).
Milrinone is a vasodilator that inhibits phosphodiesterase 3 enzymes
and is used in treatment of cardiovascular diseases [88].1694Additionally, it was shown that the milrinone with IgG caused a de-
crease in mortality in Enterovirus 71 brainstem encephalitis. But
there is no direct evidence that milrinone has antiviral effect against
the virus [89]. Milrinone was bound to the only two (Lys288 and
Leu405) residues in the ATP-binding pocket of mutant helicase (Sup-
plement File 2, Fig. 3). In addition to all this, drugs having interaction
potency on SARS-CoV-2 helicase based on our molecular docking
studies should also be evaluated by experimental methods.
4. Conclusion
Since the COVID-19pandemic occurred in early 2020, scientists have
been competing to find an effective treatment method and remedy. In
this study, we have focused on the SARS-CoV-2 helicase NTP-binding
pocket as a target site for the identification of possible FDA-approved
drugs for repositioning in COVID-19 treatment. We have detected
some mutations that may be an early indication of evolution of the
virus, on SARS-CoV-2 isolate genomes. These mutations (P504L and
Y541C) caused important exchanges in functional domain 2A of
Nsp13 (helicase), a critical enzyme in the life cycle of the virus. Molecu-
lar dynamics simulations showed that themutations caused 2A, 1A and
1B domains to move away from each other, and thus the shape of ATP-
binding site changed in mutant SARS-CoV-2 helicase. Results of high-
throughput virtual screening indicated that the four candidate drugs
(cangrelor, fludarabine, folic acid and polydatin) interacted with both
mutant and wild type helicases. Other than these four drugs, drugs ap-
proved by the FDA for the treatment of various diseases have also
been shown to interact with the ATPase functional site of mutant and
wild type SARS-CoV-2 helicase. Clinical trials and in vitro experiments
supporting these findings would be of great importance towards over-
coming COVID-19.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ijbiomac.2020.09.138.
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